Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

This study evaluates the more suitable treatment for the prevention of vascular complications in diabetes patents who were at high cardiovascular risk group by comparing the platelet aggregation inhibitory effect of aspirin and cilostazol.

Diabetes is a dangerous disease with high risk of vascular complications. Thus, to prevent these vascular complication, antithrombotic drug may be administered. Representative antithrombotic agents are aspirin and cilostazol. However, recent studies suggested that aspirin did not have sufficient effect to prevent vascular complications of diabetes. For that reason, it have been reported that antithrombotic effects of aspirin were falling in diabetes patients, so-called 'aspirin resistance.

On the other hand, cilostazol used as the control drug inhibits atherosclerosis in diabetes patients in the studies of Asia including Korea, and it is effective to inhibit the risk of various cardiovascular disease. Therefore, cilostazol is likely to use drugs as substitute for aspirin therapy.

Inclusion Criteria:

• Who have one more following risk factor:

  • Family history of cardiovascular disease
  • Hypertension
  • Smoking History
  • Dyslipidemia
  • Albuminuria

• Who do not have high risk of bleeding

• Who stop taking Cilostazol or Aspirin before randomized period 1months or

• Who have never taken the drugs

Exclusion Criteria:

• Type 1 diabetes mellitus, gestational diabetes
• Who with history of macrovascular complication including cardiovascular disease, cerebrovascular disease and peripheral vascular disease